OLX 304A
Alternative Names: OLX-304ALatest Information Update: 28 Jun 2023
At a glance
- Originator OliX Pharmaceuticals
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in South Korea (Ophthalmic)
- 28 May 2021 Olix Pharmaceuticals has patent protection for asiRNA technology in South Korea, Europe, Japan, Australia and China (Olix Pharmaceuticals website, May 2021)
- 28 May 2021 Olix Pharmaceuticals has patent protection for cp-asiRNA technology in South Korea, USA, Europe, Japan and China (Olix Pharmaceuticals website, May 2021)